HUMA

Insider Trades

Name	Value	Action	Price	Current Price
Sebelius KathleenDirector $50k56.8k shares BuyMay 19, 2026 $0.88 --
Parikh Shamik JChief Medical Officer $41k45.9k shares SellMay 18, 2026 $0.8967 --
Sander Dale A.CFO And Chief Corp. Dev. Off $41k45.9k shares SellMay 18, 2026 $0.8967 --
Constantino Michael T.Director $9.8k11k shares BuyMay 18, 2026 $0.8945 --
Dougan Brady WDirector $935k591.7k shares SellAug 20, 2025 $1.58 --
Niklason Laura EDirector, Officer: President, CEO And Director $935k591.7k shares SellAug 20, 2025 $1.58 --

News

zacks.comHumacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Knowzacks.comJun 16

seekingalpha.comHumacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcriptseekingalpha.comJun 15

zacks.comHumacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Knowzacks.comJun 15

globenewswire.comHumacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meetingglobenewswire.comJun 15

globenewswire.comHumacyte, Inc. Announces Pricing of Public Offering of Common Stockglobenewswire.comJun 10

Trade HUMA

About Humacyte, Inc.

Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.

CEO: Laura E. Niklason
IPO Date: Dec 1, 2020

Market Data

Open: $0.987
High: $1.00
Low: $0.9002
Volume: 11M
Avg Volume: 8.1M
52W High: $2.84
52W Low: $0.547

Valuation

Market Cap: $155M
Enterprise Value: $173M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-106M
Revenue: $2.0M
Net Income: $-41M
Cash: $50M
Debt: $65M

Events

EarningsAug 10

EPS est. -0.08